EP1023065A1 - Granules exempts d'excipients - Google Patents

Granules exempts d'excipients

Info

Publication number
EP1023065A1
EP1023065A1 EP98948983A EP98948983A EP1023065A1 EP 1023065 A1 EP1023065 A1 EP 1023065A1 EP 98948983 A EP98948983 A EP 98948983A EP 98948983 A EP98948983 A EP 98948983A EP 1023065 A1 EP1023065 A1 EP 1023065A1
Authority
EP
European Patent Office
Prior art keywords
granules
anyone
amoxicillin
sieving
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98948983A
Other languages
German (de)
English (en)
Inventor
Jan Willem Groenendaal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke DSM NV
Original Assignee
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM NV filed Critical DSM NV
Priority to EP98948983A priority Critical patent/EP1023065A1/fr
Publication of EP1023065A1 publication Critical patent/EP1023065A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Definitions

  • the present invention relates to granules free of excipients and a process to prepare the same.
  • crystalline antibiotic powder itself is not suitable for the manufacturing of tablets and capsules containing oral grade antibiotics such as penicillins or cephalosporins because the crystalline material has no satisfactory flowability and density so that controlled dosage per tablet or capsule is not guaranteed. Therefore, normally a granulate is produced first by mixing the crystalline product ( 1 -30 ⁇ m) with a small amount of organic solvent (e.g. alcohol and/or water) . It is preferred then to admix other components as binders (e.g. PVP) and fillers (e.g. lactose) for obtainment of granulates with satisfactory particle size distribution and strength. However, it will not be possible to achieve a high dosage per tablet unless relatively large tablets are made.
  • organic solvent e.g. alcohol and/or water
  • the granulation process generally takes place in a high shear mixer granulator by which dense particles of a suitable particle size distribution are produced. After the granulation process the material (particles of approximately 400-500 ⁇ m average diameter) is dried. It is found that while using only water as binding agent (i.e. no alcohol, no further binding agents) the batch-wise operated high shear granulators can not give a satisfactory particle size distribution while excessive fouling of the apparatus occurs.
  • Difficulties one may encounter by using dry granulation are: - a lot of dust is produced during the slugging or roller compaction process and in some cases, for example such as amoxicillin, this dust sticks to the coarser particles and can not be separated by currently applied vibrating sieves,
  • German patent application DE 2251 250 a process for relatively small tablets containing a high amount of antibiotic using a granulate prepared with a small (5-1 5%) amount of excipients (e.g. crystalline cellulose, binder, talc) has been described.
  • European patent EP 281 200 describes a pharmaceutical granulate comprising 35-45 wt% microcrystalline cellulose prepared by wet granulation, which granulate disintegrates quickly when immersed in water.
  • the antibiotic has been described to be mixed with excipients (e.g.
  • the present invention provides granules being free of excipients, for instance antibiotic and antihypercholesterolemic ones and preferably also substantially free of solvents. These granules are of a particle size between about 50 ⁇ m and 1 500 ⁇ m, preferably between about 1 25 ⁇ m and 1 000 ⁇ m.
  • antibiotic granules are those of penicillins, cephalosporins, tetracyclines and macrolides.
  • penicillins are preferably amoxicillin, ampicillin, penicillin V, oxacillin, cloxacillin, flucloxacillin, dicloxacillin and pharmaceutically acceptable salts thereof, preferably potassium salt of penicillin V, sodium salt of cloxacillin, sodium salt of flucloxacillin and sodium salt of dicloxacillin.
  • cephalosporins are preferably cephalexin, cefaclor, cefadroxil and cephradine.
  • tetracyclines are tetracycline, chlorotetracycline, oxytetracycline, doxycycline, minocycline, demeclocycline and acid salts thereof, preferably the HCI salts.
  • macrolides are preferably erythromycin, clarithromycin, roxithromycin, azithromycin and stearates, estolates, propionates, ethylsuccinates thereof.
  • antihypercholesterolemic compounds are lovastatin, simvastatin and pravastatin.
  • the process comprises of feeding, for example, an antibiotic powder corresponding to said granules to a roller compactor to produce compacts, followed by milling to give granules. These granules are, then, sieved with a sieving device to separate the granules from fine particles with a size of ⁇ 1 50 ⁇ m, preferably ⁇ 1 25 ⁇ m.
  • the sieving device preferably comprises an air jet system. The fine particles are optionally recirculated to the roller compactor.
  • the granules, prepared according to the present invention are suitable to prepare oral dosage forms such as tablets, capsules, syrups, sachets, dry instant or ready to use and multiple or single dose.
  • the oral dosage form, comprising granules free of excipients also contain a ⁇ -lactamase inhibitor such as potassium clavulanate, preferably in granule form. Said granules can also be used in Dose Sipping devices.
  • the granulation method wherein the use of excipients has been avoided, consists of dry granulation by using compaction forces to build up agglomerates. This may be performed by slugging or roller compacting. The compacts are milled and, then, sieved with a sieving device. The separation of fine particles from coarse granules may be carried out by a dry sieving or wet sieving procedure.
  • the sieving device comprises preferably an air jet system. Furthermore, the sieving device can be coupled directly to the roller compactor or stand separately from the same.
  • the application of this granulation method results in granules of penicillins, cephalosporins, tetracyclines, macrolides and antihypercholesterol compounds with a satisfactory particle size distribution, viz. between 50 ⁇ m and 1 500 ⁇ m, preferably between 1 25 ⁇ and 1 000 ⁇ m.
  • these granules are preferably substantially free of organic solvents and/or water, because during the process of compaction, use of these solvents are usually avoided.
  • the only traces of solvent(s) that may be present in the said granules are either already present in the starting compound or result from wet sieving operation.
  • a certain amount of antibiotic powder to be granulated for instance amoxicillin trihydrate, is fed to a roller compactor.
  • the compact materials are milled and, thereafter, sieved by using an air jet system.
  • the sieving device is coupled directly to the roller compactor in order to avoid extra steps or stands separately.
  • the fine particles, preferably the material ⁇ 1 25 ⁇ m, are recycled to the roller compacting process.
  • the granules free of excipients can be used for all formulations to produce chew, swallow, disperse, effervescent or normal tablets of all sizes, forms and weights, also to fill hard gelatin capsules and to formulate dry syrups and for administering drugs with the help of a dose sipping device.
  • These granules can also be used, for instance, in a pharmaceutical composition as a tablet of amoxicillin trihydrate produced from granules of amoxicillin trihydrate and potassium clavulanate (in ratio of 1 -20: 1 as, for example, described in European patent EP 49061 and International patent application WO 9709042) as a powder or in granule form.
  • the granules can be placed over a support in a tube having a liquid inlet end and a liquid outlet end; excipients can also be placed over the support, together with the drug granules.
  • Oral administration of therapeutical agents with the help of a Dose Sipping Device has been described in European patent application EP 383503.
  • the resulting granulates containing antibiotics or antihypercholesterol compounds show all-around technological properties for the production of all oral dosage forms like tablets, capsules, syrups, sachets, dry instant or ready to use, multi dose or single dose and for dose sipping devices,
  • a pharmaceutical composition of granules of ⁇ -lactams for instance amoxicillin trihydrate and a ⁇ -lactam inhibitor, for instance clavulanic acid or a pharmaceutical acceptable salt thereof, or sulbactam, preferably in the granule form, have been provided for.
  • the granules of the ⁇ -lactam inhibitor optionally contain an excipient.
  • Amoxicillin trihydrate powder was fed to a Fitzpatrick roller compacter type Chilsonator 4L X 1 0D.
  • the used rolls had a diameter of 25.4 cm and a roll wide of 1 0.2 cm, the roll surface was sinus waved grooved, the roll gap was 3.1 mm.
  • the roll speed was 1 1 rpm
  • the horizontal feeder speed was 1 7 rpm
  • the applied roll pressure 1 1 00 psi.
  • Example 1 Production of amoxicillin granulate by roller compacting using air sieving.
  • a Minox sieve type MTS 1 200 equipped with an air jet system was used instead of a vibrating sieve.
  • the sieve applied had a diameter of 1 20 cm and apertures of 1 50 ⁇ m.
  • the air was escaping upwards from a rotating perforated blade fixed horizontal under the sieve.
  • the fine particles were blown of from the coarse particles and sucked downwards through the sieve to the receiver by the action of an under pressure.
  • the fines ⁇ 1 50 ⁇ m were recycled from the receiver to the roller compacting process.
  • Vibrating sieve The following three analytical sieving methods were used to separate fine from coarse particles amoxicillin granulate: Vibrating sieve:
  • Air sieve A sieve with a diameter of 20 cm, known weight and apertures of 1 25 ⁇ m was put on a Hosokawa Alpine air sieve type 200 LS-N, 20 g amoxicillin granulate was weighed and put on the sieve. The air sieve was activated during 3 minutes, whereafter the amount of amoxicillin was determined by weighing the sieve. The test was repeated with a 250 and 1 000 ⁇ m sieve.
  • Example 3 Flowability of amoxicillin granulate of preparation 1 .
  • the class of flowability was determined using the classification of table 2.
  • amoxicillin granulate of example 1 did not flow through the funnel with a diameter of 1 8 mm so this material shows a poor flowability.
  • a graduated cylinder of 250 ml was filled carefully with amoxicillin granulate up to the 250 ml mark, the weight of the amoxicillin was determined and the loose bulk density was calculated in g/ml.
  • the cylinder was tapped using an Engelsmann Volumeter until the volume did not change more than 2 ml after 1 00 taps, the decreased volume was determined and the tapped bulk density was calculated in g/ml.
  • the compressibility was calculated according to the following formula: (tapped bulk density - loose bulk density) x 1 00%
  • the class of flowability was determined using the classification of table 3.
  • amoxicillin granulate of example 1 showed the following results:
  • Example 4 Separation of fine from coarse amoxicillin granulate particles of example 1
  • Example 5 Flowability of amoxicillin granulate of example 1
  • the flowability method using the funnels according to Lerk mentioned in example 3 was used.
  • the amoxicillin granulate of example 1 did flow smoothly through the funnel with a diameter of 5 mm so this material showed a good flowability.
  • amoxicillin granulate of example 1 showed the following results:
  • Example 6 Production of tablets containing amoxicillin granulate of example 1
  • Example 7 Production of four different formulations of tablets containing amoxicillin granulate of example 1
  • compositions of the tablet formulations are provided.
  • Amoxicillin granules and the excipients were weighed according to the above compositions and mixed during 5 minutes in a Turbula mixer, the total weight of the materials was about 100 g.
  • Amoxicillin granulate (prepared from amoxicillin trihydrate according to example 1 ) was filled into hard gelatine capsules on a Robert Bosch GKF 1 200 S capsule filling machine using continuous motion with tamping and a speed of about 65,000 capsules per hour.
  • the temperature was between 20 and 25 °C and the relative humidity ⁇ 20%.
  • Amoxicillin granules were prepared according to example 1 , the water activity of the granules was less than 0.2 at 25 ° C, which was obtained by drying the granules during 30 minutes at 40 °C and reduced pressure in a rotating mixer.
  • Potassium clavulanate granules were prepared as follows:
  • Potassium clavulanate powder with a water activity of less than 0.2 at 25 ° C was mixed with microcrystalline cellulose (Avicel ® PH 1 1 2 with a water activity of less than 0.2 at 25 °C). The mixture was then fed to a roller compactor. The produced compacts were milled with an oscillating Frewitt sieve equipped with a screen with 1 000 ⁇ m apertures.
  • the milled material was classified using a vibration sieve equipped with a 420 ⁇ m screen on top and a 1 50 ⁇ m screen equipped with an air jet system on the bottom.
  • the material coming from the top of the 420 ⁇ m screen and from the top of the 1 50 ⁇ m screen was transferred to a batch mixer, the fine material from the bottom of the sieve was transferred back to the roller compactor.
  • the granules were ready for further processing into tablets.
  • the tablets were prepared as follows:
  • Potassium granulate granules ( 1 .52 kg) with a potency of 41 .1 % clavulanic acid, amoxicillin trihydrate granules (2.925 kg) with a potency of 85.5% amoxicillin, 0.047 kg magnesium stearate, and 0.1 62 kg microcrystalline cellulose (Avicel ® PH 1 1 2 with a water activity of less than 0.2 at 25 °C) . were mixed.
  • Tablets were pressed using a Korsch EKO excenter tablet press with the following characteristics: diameter 1 8 mm, weight 950 mg, thickness 6 mm, hardness between 1 1 0 and 1 50 N, disintegration in water of 20 °C in less than 60 seconds, dissolution of the labelled amount of amoxicillin within 30 minutes by using the method as described in the U.S. Pharmacopoeia XXIII 1 994, The United States Pharmacopoeial Convention Inc. Rochville MD, USA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des granules exempts d'excipients pouvant être mis en application dans toutes les formulations pharmaceutiques. Elle concerne également un procédé servant à préparer ces granules au moyen d'un dispositif de tamisage comportant, de préférence, un système à jet d'air.
EP98948983A 1997-08-29 1998-08-27 Granules exempts d'excipients Withdrawn EP1023065A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98948983A EP1023065A1 (fr) 1997-08-29 1998-08-27 Granules exempts d'excipients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97202651 1997-08-29
EP97202651 1997-08-29
PCT/EP1998/005902 WO1999011261A1 (fr) 1997-08-29 1998-08-27 Granules exempts d'excipients
EP98948983A EP1023065A1 (fr) 1997-08-29 1998-08-27 Granules exempts d'excipients

Publications (1)

Publication Number Publication Date
EP1023065A1 true EP1023065A1 (fr) 2000-08-02

Family

ID=8228682

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98948983A Withdrawn EP1023065A1 (fr) 1997-08-29 1998-08-27 Granules exempts d'excipients

Country Status (5)

Country Link
EP (1) EP1023065A1 (fr)
CN (1) CN1268888A (fr)
AU (1) AU9540898A (fr)
TR (1) TR200000529T2 (fr)
WO (1) WO1999011261A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209099C (zh) † 1999-04-01 2005-07-06 Dsm公司 结晶化附聚物
WO2001043766A1 (fr) * 1999-12-14 2001-06-21 Asahi Kasei Kabushiki Kaisha Granules de sulfate de colistine
AT412344B (de) * 2001-04-12 2005-01-25 Sandoz Ag Hydrophobisierte teilchen von k-clavulanat
AT413983B (de) * 2001-04-12 2006-08-15 Sandoz Ag K-clavulanat in der form eines granulates
AT500131A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Organische verbindungen
EP1474104A2 (fr) * 2002-02-01 2004-11-10 Sandoz Ag Granulats stables a la segregation
AT500132A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Organische verbindungen
AT500134A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
AT500133A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
JP4949827B2 (ja) * 2003-03-21 2012-06-13 ディーエスエム アイピー アセッツ ビー．ブイ． アモキシシリン三水和物
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
EP1786548B1 (fr) * 2004-06-30 2014-12-24 DSM Sinochem Pharmaceuticals Netherlands B.V. Produit contenant un antibitique bêta-lactame
AU2006222061B2 (en) 2005-03-03 2011-04-28 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
FI20080353A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
FI20060990A0 (fi) * 2006-11-10 2006-11-10 Iprbox Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080346A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi lisäaineita sisältävän tabletin valmistamiseksi
FI20080355A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi metforminia käsittävien tablettien valmistamiseksi
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080348A0 (fi) * 2008-02-15 2008-05-09 Atacama Labs Oy Uudenlainen farmaseuttinen formulaatio
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20080352A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
EP2125707B1 (fr) 2007-01-26 2014-03-05 DSM IP Assets B.V. Procédé de fabrication d'esters 2-cyano cinnamiques substitués
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
WO2009135946A1 (fr) 2008-05-09 2009-11-12 Atacama Labs Oy Procédé et appareil de granulation par voie sèche
IT1394597B1 (it) 2008-11-05 2012-07-05 Politi Granulazione a secco in flusso di gas.
IN2015DN01093A (fr) * 2012-08-28 2015-06-26 Dsm Sinochem Pharm Nl Bv
BE1021312B1 (nl) * 2014-07-30 2015-10-28 Nordic Specialty Pharma Bvba Dicloxacillin capsule
CN105832694A (zh) * 2016-03-25 2016-08-10 海南汤臣史克生物科技有限公司 一种青霉素类药物胶囊及其制法
CN106088893B (zh) * 2016-07-28 2017-11-28 谭芳 隐藏式闭门器

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
JPS6238A (ja) * 1985-03-12 1987-01-06 Sankyo Co Ltd 混合ビタミン凍結乾燥製剤の製法
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
DE3927810A1 (de) * 1989-08-23 1991-02-28 Basf Ag Riboflavingranulate
GB9009473D0 (en) * 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9911261A1 *

Also Published As

Publication number Publication date
WO1999011261A1 (fr) 1999-03-11
TR200000529T2 (tr) 2000-08-21
CN1268888A (zh) 2000-10-04
AU9540898A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
WO1999011261A1 (fr) Granules exempts d'excipients
EP0330284B1 (fr) Procédé de préparation d'un granulé pharmaceutique
AU2002237462B2 (en) Oral pharmaceutical composition of cefpodoxime proxetil
KR101641517B1 (ko) Ｂｉｂｗ 2992를 포함하는 약제학적 고체 제형
CA2668647C (fr) Granules, comprimes et granulation
CA2272402A1 (fr) Granules comprenant du clavulanate et un ou plusieurs excipients
US8632819B2 (en) Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
AU2002237462A1 (en) Oral pharmaceutical composition of cefpodoxime proxetil
SK176798A3 (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
RU2262922C2 (ru) Способ прессования для получения лекарственной формы фенитоина натрия
KR20060135853A (ko) 디벤조[ｂ,ｅ]옥세핀 유도체를 함유하는 고형제
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
JP2000516601A (ja) 水溶性化合物及びセルロースを含有する粒状物
MXPA00002060A (en) Granules free of excipients
JP2004517111A (ja) シタロプラムを含有する薬学的調合物
KR101509489B1 (ko) 발사르탄을 함유하는 고형 경구제형의 제조 방법
DE3903217A1 (de) Verfahren zur herstellung fester pharmazeutischer zubereitungen
MXPA99006619A (en) Granules comprising clavulanate and one or more excipients
JPH07291869A (ja) 経口投与用製剤
EP2257278A1 (fr) Compositions de comprimés oraux contenant du natéglinide et un système agent tensioactif-agent de réglage du ph
AU2002253480A1 (en) Compaction process for manufacture of sodium phenytoin dosage form

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000216;LT PAYMENT 20000216;LV PAYMENT 20000216;MK PAYMENT 20000216;RO PAYMENT 20000216;SI PAYMENT 20000216

17Q First examination report despatched

Effective date: 20000927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010208